WW BIS SUP COMBINATION PRODUCT SUPPOSITORIES

Indications

• Diarrhea
• Dyspepsia
• Gastritis
• Peptic ulcer disease
• Helicobacter pylori eradication

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Bismuth exerts its therapeutic effects primarily by coating the mucosal lining of the gastrointestinal tract, which protects it from irritants and helps to reduce inflammation. It also has antimicrobial properties that may help to eradicate Helicobacter pylori, a bacterium associated with peptic ulcers. The exact mechanisms at the molecular level include the formation of a protective barrier and the inhibition of bacterial growth.

Pharmacodynamics

Bismuth compounds demonstrate a protective effect on the gastric mucosa, promoting healing in ulcerative and inflammatory conditions. The antimicrobial properties of bismuth also contribute to its efficacy in treating gastrointestinal infections, particularly those caused by H. pylori. Additionally, bismuth exhibits mild antisecretory effects, which can help to alleviate symptoms of diarrhea.

Pharmacokinetics

Bismuth is poorly absorbed from the gastrointestinal tract, which allows it to exert its effects locally while minimizing systemic exposure. Following oral administration, it travels through the gastrointestinal system, where it is primarily retained in the gut. Any absorbed bismuth is excreted through the kidneys, and its half-life is relatively short due to minimal systemic absorption.

Contra-indications

• Hypersensitivity to bismuth or any of its components
• Active gastrointestinal bleeding
• Severe renal impairment

Adverse effects

• Constipation
• Darkening of the tongue
• Stool discoloration
• Nausea
• Vomiting
• Abdominal pain

Interactions

• Bismuth subsalicylate + aspirin: Severe (increases risk of adverse effects)
• Bismuth subsalicylate + drugs with anticoagulant effects: Unknown (increases risk of bleeding events)
• Bismuth subsalicylate + see table P: Unknown (increases risk of bleeding events)

Precautions

• Use with caution in patients with renal impairment
• Avoid use in patients with a history of gastrointestinal ulcers or bleeding
• Not recommended for use in children with viral infections (risk of Reye's syndrome)

Pregnancy

Use with caution. Consult with a healthcare professional prior to use.

Breast-feeding

Considered compatible with breastfeeding but should be used only if necessary.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Bismuth subsalicylate oral suspension
• Bismuth subsalicylate chewable tablets

Dosage

Children: Refer to specific product guidelines or BNF for Children for accurate dosing information based on the formulation and indication.

Adults: Refer to specific product guidelines or BNF for accurate dosing information based on the formulation and indication.

Mechanism of action

The mechanism of action of compounds varies depending on their specific components. Generally, compounds can work through synergistic effects where the combined action of the ingredients leads to enhanced therapeutic outcomes. This may involve interactions at specific receptor sites, modulation of enzyme activity, or alteration of physiological pathways.

Pharmacodynamics

Pharmacodynamics of compounds is dependent on the individual pharmacological properties of each active ingredient within the formulation. This can include effects on receptor binding, ion channel modulation, and influence on neurotransmitter levels, leading to a range of therapeutic effects such as analgesia, anti-inflammatory action, or antimicrobial activity.

Pharmacokinetics

Pharmacokinetics of a compound involves the absorption, distribution, metabolism, and excretion of the active ingredients. Depending on their chemical nature, some compounds may exhibit rapid absorption, while others may have prolonged release characteristics. The bioavailability and half-life of each component can differ significantly, affecting overall efficacy and safety profiles.

Pregnancy

Use only if clearly needed, as safety in pregnancy is not established.

Breast-feeding

Caution is advised, as it is not known if the drug is excreted in human milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Acute diarrhea
• Chronic diarrhea
• Gastrointestinal upset
• Mild gastrointestinal inflammation

Dosage

Children: Refer to BNF for Children for specific dosing guidance.

Adults: Refer to BNF for specific dosing guidance.

Mechanism of action

Subgallate exerts its effects mainly through its astringent action, which leads to the precipitation of proteins in the gastrointestinal tract. This process results in the formation of a protective barrier that helps to reduce fluid secretion, enhances mucosal integrity, and decreases stool frequency. It also promotes the absorption of fluids and electrolytes, aiding in the management of diarrhea.

Pharmacodynamics

The pharmacodynamics of subgallate involve its ability to bind to proteins and mucins in the gastrointestinal lining, thereby providing a protective effect against irritants and inflammatory agents. Its astringent properties help reduce secretions and increase the absorption of fluids in the intestines. Subgallate may also have mild antibacterial effects, contributing to its efficacy in treating certain types of diarrhea.

Pharmacokinetics

Subgallate is not extensively absorbed systemically and primarily acts locally within the gastrointestinal tract. After administration, it exerts its therapeutic effects directly where it is required. The onset of action is relatively rapid, and the duration of effect can vary depending on the formulation and individual patient factors. Metabolism and excretion details for subgallate are limited, but it is generally eliminated from the gastrointestinal tract without significant systemic absorption.

Pregnancy

Subgallate may be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Consult healthcare professionals for specific guidance.

Breast-feeding

It is unknown whether subgallate is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.